Digoxin pharmacokinetics

V. P. Butler, Jr., D. H. Schmidt, T. W. Smith, E. Haber, B. D. Raynor, andP. Demartini, Effects of sheep digoxin-specific antibodies and their Fab fragments on digoxin pharmacokinetics in dogs, J. Clin. Invest. 59, 345-359 (1977). 

Becquemont L, Verstuyft C, Kerb R, et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 2001 70(4) 311-316. 

Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, Funck-Brentano C. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 2003 58 809-812. 

Larsen F, Priskorn M, Overo KF. Lack of citalopram effect on oral digoxin pharmacokinetics. J Clin Pharmacol 2001 41(3) 340-6. 

Sanchez Garcia P, Paty I, Leister CA, Guerra P, Frias J, Garcia Perez LE, Darwish M. Effect of zaleplon on digoxin pharmacokinetics and pharmacodynamics. Am J Health Syst Pharm 2000 57(24) 2267-70. 

Levy RH, Ragueneau-Majlessi I, Baltes E. Repeated administration of the novel antiepileptic agent levetirace-tam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res 2001 46(2) 93-9. 

Button C, Gross D R, Johnston J T et al 1980 Digoxin pharmacokinetics, bioavailability, efficacy and dosage regimens in the horse. American Journal of Veterinary Research 41 1388-1395... 

Drug interactions with hawthorn are theoretically possible with cardioactive medications, but have not been documented (2). In addition, the flavonoid constituents have been shown to have inhibitory and inducible effects on the cytochrome P-450 enzyme system, making other drug interactions possible (20). However, an in vivo study of a potential pharmacokinetic interaction of digoxin and hawthorn demonstrated that concurrent administration had no effect on digoxin pharmacokinetics, suggesting that the two could be safely administered together from a pharmacokinetic point of view (21). However, one must be mindful of additive effects and a potential pharmacodynamic interaction. 

Gibson, T.P. Nelson, H. A. (1980) Digoxin alters quinidine and quinidine alters digoxin pharmacokinetics in dogs. Journal of Laboratory Clinical Medicine, 95, 417-428. 

Horn, J.R. Christensen, D.B. deBlaquire, P.A. Evaluation of a digoxin pharmacokinetic monitoring service in a community hospital. Drug Intell. Clin. Pharm. 1985, 19, 45 52. 

Koup JR, Jusko WJ, Elwood CM, KohU RK. Digoxin pharmacokinetics Role of renal failure in dosage regimen design. CUn Pharmacol Ther 1975 18 9-21. 

ABCBl (MDRl) Digoxin Pharmacokinetic parameters TT homozygous C3435T associated with higher plasma concentrations 48... 

Chowbay B, Li H, David M, et al. (2005). Meta-analysis of the influence of MDRl C3435T polymorphism on digoxin pharmacokinetics and MDRl gene expression. Br. J. Clin. Pharmacol. 60 159-171. 

Disease Characteristics That Affect Digoxin Pharmacokinetics... 

Rossi GP, Semplicini A, Boi ovi S, Mozzato MG, Paleari CD, Pessina AC. Effect of acute captopril administration cn digoxin pharmacokinetics in normal subjects. Curr Ther Res (1989) 46,439. ... 

Vandenbuig MJ, Kelly JG, Wiseman HT, Mannering D, Loi C, Glover DR. The effect of lisinopril on digoxin pharmacokinetics in patients with cor estive heart failure. BrJ Clin Pharmacol 9ZZ) 21,656P-657P. 

Feuring M, Lee Y, Orlowski LH, Michiels N, De Smet M, Majumdar AK, Petty KJ, Goldberg MR, Murphy MG, Gottesdiener KM, Hesney M, Brackett LE, Wehling M. Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects. J Clin Pharmacol (2003) 43, 912-17. 

Edner M, Jogesttand T, Dahlqvist R. Effect of salbutamol on digoxin pharmacokinetics. EurJ Clin Pharmacol ( 992) 42,197-201. 

Talinolol. In healthy subjects talinolol 100 mg orally substantially increased the bioavailability of a single 500-microgram dose of digoxin. The AUCq 72 and the maximum serum levels of digoxin were increased by 23% and 45%, respectively. Conversely, intravenous talinolol 30 mg had no effect on digoxin pharmacokinetics. ... 

Beltrami TR, May JJ, Beitino JS. Lack of effects of diltiazem on digoxin pharmacokinetics. 

Nevertheless, the changes in digoxin pharmacokinetics are unlikely to be clinically relevant, and no digoxin dose adjustment is likely to be required on concurrent use. 

Gurley BJ, Swain A, Barone GW, Williams DK, Breen P, Yates CR, Stuart LB, Hubbard MA, Tong Y, Cheboyina S. Effect of goldenseal Hydrastis canadensis ) and kava kava (piper methysticum) supplementation on digoxin pharmacokinetics in humans. Dn Metab Dispos (2007) 35, 240-5. 

---